Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer
| Autor: | Maria Merino, M. Minhaj Siddiqui, Mahir Maruf, Hui Han, Arvin K. George, Peter L. Choyke, Howard L. Parnes, Peter A. Pinto, Akhil Muthigi, Thomas Frye, Baris Turkbey, Michael Kongnyuy, Brad Wood, Amichai Kilchevsky |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Image-Guided Biopsy
Male medicine.medical_specialty Urology 030232 urology & nephrology Magnetic Resonance Imaging Interventional Article 03 medical and health sciences Prostate cancer 0302 clinical medicine Predictive Value of Tests Biopsy medicine Humans In patient Fusion Biopsy Multiparametric Magnetic Resonance Imaging Ultrasonography Interventional Aged Retrospective Studies medicine.diagnostic_test business.industry Ultrasound Prostatic Neoplasms Magnetic resonance imaging Middle Aged equipment and supplies medicine.disease Prostate-specific antigen 030220 oncology & carcinogenesis Population Surveillance Disease Progression Radiology business human activities |
| Zdroj: | J Urol |
| ISSN: | 1527-3792 |
| Popis: | PURPOSE: Active surveillance is an established option for men with low risk prostate cancer. Multiparametric magnetic resonance imaging with magnetic resonance imaging-transrectal ultrasound fusion guided biopsy may better identify patients for active surveillance compared to systematic 12-core biopsy due to improved risk stratification. To our knowledge the performance of multiparametric magnetic resonance imaging in following men on active surveillance with visible lesions is unknown. We evaluated multiparametric magnetic resonance imaging and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy to monitor men on active surveillance. MATERIALS AND METHODS: This retrospective review included men from 2007 to 2015 with prostate cancer on active surveillance in whom magnetic resonance imaging visible lesions were monitored by multiparametric magnetic resonance imaging and fusion guided biopsy. Progression was defined by ISUP (International Society of Urological Pathology) grade group 1 to 2 and ISUP grade group 2 to 3. Significance was considered at p ≤0.05. RESULTS: A total of 166 patients on active surveillance with 2 or more fusion guided biopsies were included in analysis. Mean followup was 25.5 months. Of the patients 29.5% had pathological progression. Targeted biopsy alone identified 44.9% of patients who progressed compared to 30.6% identified by systematic 12-core biopsy alone (p = 0.03). Fusion guided biopsy detected 26% more cases of pathological progression on surveillance biopsy compared to systematic 12-core biopsy. Progression on multiparametric magnetic resonance imaging was the sole predictor of pathological progression at surveillance biopsy (p = 0.013). Multiparametric magnetic resonance imaging progression in the entire cohort had 81% negative predictive value, 35% positive predictive value, 77.6% sensitivity and 40.5% specificity in detecting pathological progression. CONCLUSIONS: Multiparametric magnetic resonance imaging progression predicts the risk of pathological progression. Patients with stable multiparametric magnetic resonance imaging findings have a low rate of progression. Incorporating fusion guided biopsy in active surveillance nearly doubled our detection of pathological progression compared to systematic 12-core biopsy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|